Pancreatic enucleation

Displaying 3 studies

  • A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial Rochester, MN

    The purpose of this study is to evaluate how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

  • Pancreatic Surgery Database Jacksonville, FL

    The aims of this study will be collection of standard and routinely obtained data specifically in the preoperative evaluation, operative room, postoperative/hospitalization period, and long term follow from the electronic medical record.  Data collected will then be analyzed with standard scientific methods. 

  • Aggressive Malignancy PDX (Avatar) and Cryopreservation Program Rochester, MN

    The purpose of this study is to assess the ability to successfully create numerous validated patient-derived xenograft (PDX) models from patient tumor specimens obtained at surgery/biopsy via the new Pathology/TRAG cryopreservation protocol, and to generate a large catalog and repertoire of previously unavailable histologically validated PDX.



Mayo Clinic Footer